Drug intelligence / Profile preview

ceftazidime + imipenem

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous

Overview

Combination of ceftazidime (a third-generation cephalosporin antibiotic) and imipenem (a carbapenem antibiotic) used to treat bacterial infections, particularly those caused by extensively drug-resistant Pseudomonas aeruginosa (XDRPA). This combination demonstrates synergistic activity against resistant bacteria with mechanisms such as AmpC overexpression or mutation, decreased OprD porin, and upregulated efflux pumps.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ceftazidime + imipenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftazidime + imipenem.

Explore the full profile